Sanofi (SNY) and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating invasive pneumococcal disease (“IPD”) in pediatric and adult patient populations.The latest deal builds on the existing collaboration between SNY and SK bioscience to develop and commercialize a 21-valent PCV (PCV21) for the pediatric patient population.Sanofi also said that the companies commenced a phase III p ...

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers Paris, December 23, 2024. Sanofi and SK bioscience have entered into a new chapter of thei ...

Sanofi (SNY) and partner Teva Pharmaceuticals (TEVA) announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment of Ulcerative Colitis (UC) and Crohn's disease (CD), the two main types of inflammatory bowel disease (IBD). The study met its primary endpoints for both diseases.Treatment With SNY-TEVA Drug Exhibits Best-in-Class PotentialIn the UC group, 36.2% of patients who received a low dose of the drug and 47.8% ...

Sanofi (SNY) shares soared 6.7% in the last trading session to close at $48.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.4% loss over the past four weeks.This jump in share price came after management reported positive results from a mid-stage study on its experimental anti-TL1A therapy, duvakitug, in Ulcerative Colitis and Crohn's disease, which are the two main types of inflammatory bowel disease. The study achieved it ...

Key TakeawaysTeva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.The companies plan to provide further details about the research at a scientific forum in 2025.Teva and Sanofi said they would start a Phase 3 study of the treatment pending discussions with regulators.Both pharmaeuticals companies' U.S.-traded stocks gained after the news Tuesday, with Teva at its highest level in six years. U.S.-traded shares of Tev ...

On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA’s SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD).RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD).In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission c ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory discussionsProgram underscores Sanofi's Immunology leadership ambitio ...

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanof ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS)Tolebrutinib is the first and only brain-penetrant BTK inhibitor in MS to be designated Breakthrough Therapy by the FDA  Paris, December 13, 2024. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for ...

A Sanofi logo sits on the facade of the company's headquarters on December 11, 2020 in Gentilly near Paris, France.SINGAPORE — French pharmaceutical giant Sanofi on Wednesday opened a 800 million Singapore dollar ($595 million) "evolutive vaccine facility," or EVF, in Singapore — the only such facility the company has outside of France.This plant, known as Modulus, can switch between making different vaccines or treatments in a matter of days, compared to several weeks or months in more conventional facilit ...